Mineralys CCO reports initial stock holdings

Mineralys Therapeutics, Inc. filed an initial ownership report for Chief Commercial Officer Warren Eric.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. filed an initial ownership report for Chief Commercial Officer Warren Eric. It shows direct holdings of stock options covering 357,000 shares and another 51,300-share option, plus 38,400 shares of common stock. Footnotes describe restricted stock units granted for no cash consideration that vest over four years starting on February 19, 2026. One option grant vests 25% on the first anniversary of April 21, 2025, with the rest vesting in 36 monthly installments, while another vests in 48 equal monthly installments beginning after February 19, 2026.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Warren Eric

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
holding	Stock Option	--	--	--
holding	Stock Option	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Stock Option — 408,300 contracts (Direct); Common Stock — 38,400 shares (Direct)

Footnotes (3)

1. F1. Represents restricted stock units (RSUs) that were granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of February 19, 2026, the date of grant.
2. F2. The stock option vests as to 25% of the underlying shares on the first anniversary of April 21, 2025, the date of grant, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.
3. F3. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following February 19, 2026, the date of grant.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Mineralys Therapeutics (MLYS) Form 3 for Warren Eric report?

The Form 3 reports Chief Commercial Officer Warren Eric’s initial beneficial ownership in Mineralys Therapeutics, including stock options, common shares, and restricted stock units that vest over multi‑year schedules starting in 2025 and 2026.

How many stock options does Mineralys Therapeutics CCO Warren Eric hold?

Warren Eric holds two direct stock option positions: one covering 357,000 shares and another covering 51,300 shares. These options vest over time according to specified schedules beginning on April 21, 2025, and February 19, 2026, respectively.

What common stock ownership is disclosed for Warren Eric at Mineralys Therapeutics (MLYS)?

The filing discloses that Warren Eric directly owns 38,400 shares of Mineralys Therapeutics common stock following the reported transactions. This represents his direct equity stake in the company’s common shares as of the Form 3 reporting date.

How do Warren Eric’s restricted stock units at Mineralys Therapeutics vest?

His restricted stock units were granted for no additional cash consideration and vest in four annual installments. One quarter of the RSUs vest on each one‑year anniversary of February 19, 2026, with each vested unit converting into one share of common stock.

What are the vesting terms of Warren Eric’s April 21, 2025 stock option grant at MLYS?

The April 21, 2025 stock option grant vests 25% of the underlying shares on the first anniversary of that date. The remaining 75% then vest in 36 substantially equal monthly installments, creating a four‑year total vesting period.

How does the February 19, 2026 stock option grant for Mineralys CCO vest?

The stock option tied to February 19, 2026 vests in 48 equal monthly installments. Each month after that grant date, 1/48th of the total shares underlying the option vest, spreading vesting evenly over four years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/04/2026 - 07:25 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Warren Eric

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

(Street)

RADNOR PA 19087

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
03/04/2026

3. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	38,400(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	(2)	04/21/2035	Common Stock	357,000	$13.24	D
Stock Option	(3)	02/19/2036	Common Stock	51,300	$28.06	D

Explanation of Responses:

1. Represents restricted stock units (RSUs) that were granted to the reporting person for no additional cash consideration, each of which represents a contingent right to receive one share of common stock upon vesting. The RSUs vest in annual installments over a period of four years, with 1/4th of the total shares underlying the RSU vesting on each one-year anniversary of February 19, 2026, the date of grant.

2. The stock option vests as to 25% of the underlying shares on the first anniversary of April 21, 2025, the date of grant, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

3. The stock option vests in monthly installments over a period of four years, with 1/48th of the total shares underlying the option vesting each one-month period following February 19, 2026, the date of grant.

Remarks:

EXHIBIT LIST: Exhibit-24 Eric Warren POA

	/s/ Eric Warren	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.